Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome

BMC Medical Imaging

Volumn 16, Issue 1, 2016, Pages

  Wang, Yunzhi ^a   Qiu, Yuchen ^a   Thai, Theresa ^b   Moore, Kathleen ^b   Liu, Hong ^a   Zheng, Bin ^a  

^a University of Oklahoma   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Clinical image markers for cancer prognosis prediction; Computer aided detection (CAD); Prediction of chemotherapy outcome; Quantitative image feature analysis

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL FAT; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; DRUG THERAPY; FEASIBILITY STUDY; FEMALE; HUMAN; OVARIAN NEOPLASMS; PROCEDURES; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ABDOMINAL FAT; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LOGISTIC MODELS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84984680092     PISSN: None     EISSN: 14712342     Source Type: Journal    
DOI: 10.1186/s12880-016-0157-5     Document Type: Article

References (33)

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-5.
2. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
3. Goetsch CM. Genetic tumor profiling and genetically targeted cancer therapy. In: Seminars in oncology nursing: 2011. Philadelphia, USA: WB Saunders; 2011. p. 34-44.
4. Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabø A, Apold J, Skaane P, Møller P. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast. 2007;16(4):367-74.
5. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-92.
6. Herper M, Gene test for Pfizer cancer drug to cost $1,500 per patient, Forbes 8/29/2011; www.forbes.com/sites/matthewherper/2011/08/29/gene-test-for-pfizer-cancer-drug-to-cost-1500-per-patient. Accessed 29 Aug 2011.
7. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool opportunities and potential limitations. Mol Cell Proteomics. 2004;3(4):367-78.
8. Bhooshan N, Giger M, Edwards D, Yuan Y, Jansen S, Li H, Lan L, Sattar H, Newstead G. Computerized three-class classification of MRI-based prognostic markers for breast cancer. Phys Med Biol. 2011;56(18):5995.
9. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gillies R, Boellard R, Dekker A. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441-6.
10. Tan M, Pu J, Cheng S, Liu H, Zheng B. Assessment of a four-view mammographic image feature based fusion model to predict near-term breast cancer risk. Ann Biomed Eng. 2015;43(10):2416-28.
11. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
12. Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, Forster K, Aerts HJ, Dekker A, Fenstermacher D. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30(9):1234-48.
13. Aghaei F, Tan M, Hollingsworth AB, Zheng B. Applying a new quantitative global breast MRI feature analysis scheme to assess tumor response to chemotherapy. J. Magn. Reson. Imaging. 2016. DOI: 10.1002/jmri.25276
14. Emaminejad N, Qian W, Guan Y, Tan M, Qiu Y, Liu H, Zheng B. Fusion of quantitative image and genomic biomarkers to improve prognosis assessment of early stage lung cancer patients. IEEE Trans Biomed Eng. 2016;63(5):1034-43.
15. Qiu Y, Tan M, McMeekin S, Thai T, Ding K, Moore K, Liu H, Zheng B. Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiologica. 2015. doi:10.1177/0284185115620947
16. Tan M, Li Z, Qiu Y, McMeekin SD, Thai TC, Ding K, Moore KN, Liu H, Zheng B. A new approach to evaluate drug treatment response of ovarian cancer patients based on deformable image registration. IEEE Trans Med Imaging. 2016;35(1):316-25.
17. Ramírez J, Górriz J, Salas-Gonzalez D, Romero A, López M, Álvarez I, Gómez-Río M. Computer-aided diagnosis of Alzheimer's type dementia combining support vector machines and discriminant set of features. Inf Sci. 2013;237:59-72.
18. Olsen GF, Brilliant SS, Primeaux D, Najarian K: An image-processing enabled dental caries detection system. In: Complex Medical Engineering, 2009 CME ICME International Conference on: 2009: NJ, USA: IEEE; 2009. p. 1-8.
19. Abulafia O, Triest WE, Sherer DM. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol. 1997;177(3):541-7.
20. Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF. Risk factors for GI adverse events in a phase III randomized trial of Bevacizumab in first-line therapy of advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2014;32(12):1210-7.
21. Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP, Bookman MA. Independent radiologic review of the gynecologic oncology group study 0218, a phase III trial of Bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol. 2013;131(1):21-6.
22. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-96.
23. Teoh D, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control. 2011;18(1):31-43.
24. Guiu B, Petit JM, Bonnetain F, Ladoire S, Guiu S, Cercueil J-P, Krausé D, Hillon P, Borg C, Chauffert B. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut. 2010;59(3):341-7.
25. Slaughter KN, Thai T, Penaroza S, Benbrook DM, Thavathiru E, Ding K, Nelson T, McMeekin DS, Moore KN. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014;133(1):11-5.
26. Leader JK, Zheng B, Rogers RM, Sciurba FC, Perez A, Chapman BE, Patel S, Fuhrman CR, Gur D. Automated lung segmentation in X-ray computed tomography: development and evaluation of a heuristic threshold-based scheme 1. Acad Radiol. 2003;10(11):1224-36.
27. Yoshizumi T, Nakamura T, Yamane M, Waliul Islam AHM, Menju M, Yamasaki K, Arai T, Kotani K, Funahashi T, Yamashita S. Abdominal fat: Standardized technique for measurement at ct 1. Radiology. 1999;211(1):283-6.
28. Liou T-H, Chan WP, Pan L-C, Lin P, Chou P, Chen C-H. Fully automated large-scale assessment of visceral and subcutaneous abdominal adipose tissue by magnetic resonance imaging. Int J Obes. 2006;30(5):844-52.
29. Stroom J, Blaauwgeers H, van Baardwijk A, Boersma L, Lebesque J, Theuws J, van Suylen R-J, Klomp H, Liesker K, van Pel R. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. Int J Radiat Oncol Biol Phys. 2007;69(1):267-75.
30. Hosmer Jr DW, Lemeshow S. Applied logistic regression. Hoboken: John Wiley & Sons; 2004
31. Pudil P, Ferri F, Novovicova J, Kittler J: Floating search methods for feature selection with nonmonotonic criterion functions. In: In Proceedings of the Twelveth International Conference on Pattern Recognition, IAPR: 1994. NJ, USA: IEEE; 1994.
32. Li Q, Doi K. Reduction of bias and variance for evaluation of computer-aided diagnostic schemes. Med Phys. 2006;33(4):868-75.
33. Wang Y, Thai T, Moore K, Ding K, McMeekin S, Liu H, Zheng B. Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients. Oncol Letter. 2016;12:680-6.